A PHASE I TRIAL OF RADIOIMMUNOTHERAPY (Y-90 CT8466), GEMCITABINE AND HEPATIC

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 目的是确定在肝切除术或肝转移最大手术减积（至<3cm）后的结直肠癌患者中，同时肝动脉输注（HAI）氟脱氧嘧啶（FUdR）和静脉内吉西他滨联合静脉内钇-90嵌合T84.66的最大耐受剂量（MTD）和相关毒性;研究肝转移瘤切除和/或消融后这种辅助治疗的可行性和毒性;评估静脉内施用的钇-90和铟-111嵌合T84.66的生物分布、清除和代谢;通过连续核成像估计全身、正常器官和肿瘤的辐射剂量;将治疗前后的蛋白质组学谱与毒性和抗肿瘤效应相关联。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objectives are to determine the maximum tolerated dose (MTD) and associated toxicities of concurrent hepatic arterial infusion (HAI) fluorodeoxypyrimide (FUdR) and intravenous gemcitabine combined with intravenous Yttrium-90 chimeric T84.66 in colorectal cancer patients after hepatic resection or maximum surgical debulking (to <3cm) of liver metastases; to study the feasibility and toxicities of such adjuvant therapy following resection and/or ablation of liver metastases; to evaluate the biodistribution, clearance and metabolism of Yttrium-90 and Indium-111 chimeric T84.66 administered intravenously; to estimate radiation doses to whole body, normal organs and tumor through serial nuclear imaging; to correlate proteomic profiles pre and post-therapy with toxicities and anti-tumor effects.